All updates
All updates
today 49文献与产业新闻评分4747 文献与产业新闻精选评分5757 STAT+: Roivant lung disease drug hits mid-stage study goals
文献与产业新闻评分2525 Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
文献与产业新闻评分4242 Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending
文献与产业新闻精选评分4949 Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
文献与产业新闻精选评分5353 Boston Scientific recalls spinal cord implant in wake of more than 1k serious injuries
顶刊论文（社媒热度）精选评分6363 Tozorakimab to Prevent COPD Exacerbations.
NEJM评分00 Tozorakimab to Prevent COPD Exacerbations
文献与产业新闻精选评分5454 STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
文献与产业新闻精选评分5757 Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
顶刊论文（社媒热度）精选评分7373 Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.
顶刊论文（社媒热度）精选评分6161 Transplanted pig kidney works for record 271 days in "bridging" study.
文献与产业新闻评分2929 Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
中文产业新闻精选Chinese source评分6969 张力/杨云鹏/赵洪云团队JAMA发文：EGFR/TP53共突变晚期NSCLC一线奥希替尼联合化疗PFS显著延长
中文产业新闻精选Chinese source评分6767 诺华Pelacarsen III期折戟，中国Lp(a)研发潮迎来压力测试
中文产业新闻精选Chinese source评分7373 诺华 pelacarsen 三期 Lp(a)HORIZON 试验未达主要终点
文献与产业新闻精选评分6565 STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
The Lancet精选评分5151 [Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
顶刊论文（社媒热度）精选评分5050 Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
中文产业新闻精选Chinese source评分6464 ESC 2026报告PVI-SHAM-AF试验：消融降低房颤复发但生活质量改善未优于假手术对照
文献与产业新闻精选评分6565 Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
顶刊论文（社媒热度）精选评分6262 Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.
中文产业新闻精选Chinese source评分7373 诺华跌5%：Lp(a) ASO pelacarsen 三期临床失败
中文产业新闻精选Chinese source评分6868 诺华pelacarsen在Lp(a)HORIZON三期试验中未改善主要心血管事件
文献与产业新闻精选评分6565 STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
文献与产业新闻精选评分7272 Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
顶刊论文（社媒热度）精选评分7272 Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
顶刊论文（社媒热度）精选评分6060 Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial.
顶刊论文（社媒热度）精选评分6060 Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial.
文献与产业新闻评分3030 STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
顶刊论文（社媒热度）精选评分6161 Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial.
中文产业新闻精选Chinese source评分6060 康方依沃西头对头击败K药 HARMONi-2 III期OS期中分析达统计学显著
中文产业新闻精选Chinese source评分6565 诺华Rap-cel因3例致死IEC-HS暂停8项自免试验，BMS Zola-cel同步暂停新患者入组
顶刊论文（社媒热度）精选评分7474 [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
文献与产业新闻评分3737 STAT+: Recipients of gene-edited pig kidneys successfully receive human organs
文献与产业新闻评分2424 Ultragenyx, Alumis look ahead after late-stage losses
中文产业新闻精选Chinese source评分6666 康方依沃西单抗HARMONi-2头对头III期研究战胜K药，mPFS 11.14对比5.82个月
文献与产业新闻精选评分5353 Akeso, Summit’s ivonescimab extends lives in Keytruda head-to-head trial. What now?
文献与产业新闻精选评分3939 AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
顶刊论文（社媒热度）精选评分6767 YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.